Jeeyong Lee

- Drive business growth in protein crystallization by leveraging the unique advantages of microgravity. - Increase awareness of the benefits of utilizing microgravity conditions for bio R&D and drug development. - Foster customer development and engagement to strengthen relationships and drive success. - Establish a strong presence and commercial operations in the US market. - Build a sustainable organization focused on advancing biopharmaceutical innovations.

I truly believe that God has given me this heart-beating opportunity to embark on a new journey in Space Pharmaceuticals and Global Business Development at SpaceLiintech. SpaceLiintech is setting up its U.S. office in Boston this year, marking the beginning of an exciting global expansion — and I’m deeply honored to join the company at this pivotal milestone. In my new role, I will: - Lead SpaceLiintech’s global expansion strategy in microgravity-enabled protein crystallization, building partnerships with the global biopharma community, medical institutions, and hospitals. - Develop strategic alliances with biotech partners to enable space-based protein crystallization and advanced biologics manufacturing. - Drive U.S. business development initiatives, including SpaceLiintech’s office expansion in Boston and other states. - Advocate the vision of “Space Medicine and Innovation Beyond Gravity,” harnessing microgravity to solve complex biomedical challenges. I’m beyond excited to contribute to this groundbreaking mission — where Space medicine, innovation, and faith align beyond gravity. 🌍🚀

Lead Sanofi’s Launch Excellence framework, directing cross-functional teams for best-in-class global product launches. - Organize and guide global launch teams, collaborating with GBLs and key functional leads to develop a Launch Roadmap and monitor its progress. - Ensure all launch plans are robust and ready to implement for best-in-class industry launch. - Drive and support key markets in US, EU5, and Japan to develop local launch plans and ensure seamless implementation for a successful launch. - Lead new launch preparation for all Rare Disease Franchise pipelines.

Drove Global RD Franchise Operations projects and X-Rare disease marketing, supplementing, and complementing the efforts of the Global brand team. - Guided the annual brand planning process for the Global and Country RD franchise to develop solid brand strategies and tactics. - Led Rare disease congress strategies and plans at major congresses including WORLD, SSIEM and ICIEM, and successfully positioned Sanofi as a strong leader and pioneer over competitors. - Organized RD franchise-level cross-functional and country meetings such as the Global Rare Disease Summit, X-RARE meeting, Global RD Awards, and Competitive task-force meeting and shared Franchise updates, strategic direction, and key tactics and led the competitive workshops. - Led the development and creation of X-LSD marketing collaterals and disseminated to countries for localized sales and marketing activities.

Led Japan-Asia Pacific RD franchise marketing in more than 12 countries and business (€281M) by implementing Region RD strategies, tactics, and regional KOL engagement activities. - Developed and executed comprehensive launch strategies and initiatives for 3 new products (Cerdelga, Aubagio, Caprelsa) across JPAC region. - Strengthened Partnerships with Key Opinion Leaders (KOLs) by organizing high-impact regional advisory boards and scientific symposia, enhancing the company's brand reputation and expanding access to innovative therapies. - Revenue growth from €231M to €281M (+20%) by implementing an effective marketing campaign and regional KOL engagement activities.

Led Multiple Sclerosis Marketing and new product launch. - Established the first MS Franchise in JPAC, leading successful launches of Aubagio and Lemtrada. - 1st launch in JPAC region (except Australia), increased Aubagio brand awareness by 104% among MS specialists within 8 months and achieved the highest global market share (25%) within two years.

Secondment as JPAC liaison for Cerdelga launch preparations and develop bio-similar mitigation strategy and tactics. - Led the Welcome kit development project as part of Cerdelga launch and rolled out biosimilar mitigation strategy in EU and JPAC countries.

Executed local marketing strategies, leading projects to increase disease awareness and identify new patients. - Launched Elaprase in 2009 and Myozyme in 2010. - Identified over 100 new patients and led to revenue growth from $12M to $33M from 2007 to 2012.

Worked as the first CSA (field force) in nationwide and focused on educating targeted physicians to increase disease awareness on LSD diseases and developed KOLs. - Recognized as JPAC Sales of the Year recipient for the highest sales performance in 2008.

- Managed Diabetes, Osteoporosis, and Urology portfolios in the Dae-Jeon metropolitan region. - Executed KOL engagement programs, fostering customer relationships and consistently meeting sales targets. Key Accomplishments - Member of the Sales Leaders Club (2006) - Best Practice Presenter for delivering scientific medical information (2005) - Awarded Best Presenter and Medical Representative of the Year (2004)

- Managed ETC products in Jeon-Buk province, targeting approximately 150 physicians. - Implemented sales activities and seminars to achieve sales objectives. Key Accomplishments - Awarded Best Medical Representative of the Year (2003)